Results after at least 52 weeks of open label treatment with ixekizumab, an anti-IL-17A monoclonal antibody, in a phase 2 study in chronic plaque psoriasis

被引：0
|
作者：
Gordon, Kenneth [1 ]
Leonardi, Craig [2 ]
Braun, Daniel [3 ]
Cameron, Gregory [3 ]
Erickson, Janelle [3 ]
Lebwohl, Mark [4 ]
Heffernan, Michael [3 ]
Banerjee, Subhashis [3 ]
机构：
[1] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[2] St Louis Univ, Sch Med, St Louis, MO USA
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Mt Sinai Sch Med, New York, NY USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2014年 / 70卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P8365
引用
收藏
页码：AB183 / AB183
页数：1
相关论文
共 50 条
  • [41] TILDRAKIZUMAB, A SELECTIVE IL-23P19 ANTIBODY, IN THE TREATMENT OF CHRONIC PLAQUE PSORIASIS: RESULTS FROM TWO RANDOMIZED, CONTROLLED, PHASE 3 TRIALS
    Sinclair, R.
    Reich, K.
    Papp, K.
    Blauvelt, A.
    Tyring, S.
    Thaci, D.
    Cichanowitz, N.
    Mehta, A.
    Li, Q.
    Liu, K.
    La Rosa, C.
    Green, S.
    Kimball, A.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2017, 56 (11) : 1238 - 1239
  • [42] Tildrakizumab, a selective IL-23p19 antibody, in the treatment of chronic plaque psoriasis: Results from two randomised, controlled, phase 3 trials
    Sinclair, R.
    Reich, K.
    Papp, K.
    Tyring, S. S.
    Thaci, D.
    Cichanowitz, N.
    Blauvelt, A.
    Liu, K.
    Li, Q.
    La Rosa, C.
    Green, S. A.
    Kimball, A. B.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 9 - 10
  • [43] Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52
    Feldman, Steven R.
    Narbutt, Joanna
    Girolomoni, Giampiero
    Brzezicki, Jan
    Reznichenko, Nataliya
    Zegadlo-Mylik, Maria Agnieszka
    Pulka, Grazyna
    Dmowska-Stecewicz, Magdalena
    Klujszo, Elzbieta
    Rekalov, Dmytro
    Rajzer, Lidia
    Lee, Jiyoon
    Lee, Minkyung
    Rho, Young Hee
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [44] Bimekizumab response is maintained through 2 years of treatment in patients with moderate-to-severe plaque psoriasis who responded after 16 weeks: results from the open-label extension of BE RADIANT
    Warren, Richard B.
    de Rie, Menno
    Feldman, Steven R.
    Gooderham, Melinda
    Eyerich, Kilian
    Spelman, Lynda
    White, Katy
    Staelens, Fabienne
    Gomez, Natalie Nunez
    Strober, Bruce
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 74 - 74
  • [45] CT-P17 Adalimumab Biosimilar in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: An Open-Label Extension of a Phase 3 Interchangeability Study
    Pariser, David M.
    Lebwohl, Mark G.
    Jaworski, Janusz
    Trefler, Jakub
    Daniluk, Stefan
    Dudek, Anna
    Baran, Wojciech
    Owczarek, Witold
    Brzewski, Pawel
    Sikora, Mariusz
    Krogulec, Marek
    Kim, Sunghyun
    Suh, Jeehye
    Choi, Eunjin
    Cha, Jungbin
    Lee, Hyunjin
    Lee, Sungjeong
    Koo, John Y.
    DERMATOLOGY AND THERAPY, 2025, : 1079 - 1092
  • [46] Prevention of Episodic Migraine with AMG 334, a Human Anti-Calcitonin Gene-Related Peptide Receptor Monoclonal Antibody: Phase 2 Study Results and 52-Week Analysis of Open-Label Extension
    Lenz, Robert
    Dodick, David
    Goadsby, Peter
    Silberstein, Stephen
    Reuter, Uwe
    Ashina, Messoud
    Saper, Joel
    Cady, Roger
    Zhang, Feng
    Trotman, Marie-Louise
    Dietrich, Julie
    Sun, Hong
    NEUROLOGY, 2016, 86
  • [47] Safety and efficacy of the fully human IL-12/-23 monoclonal antibody, ABT-874, in the treatment of moderate to severe plaque psoriasis: Results from a Phase II trial
    Kimball, A. B.
    Gordon, K. B.
    Valdes, J. M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S54 - S54
  • [48] Guselkumab, a human interleukin-23 monoclonal antibody in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: Efficacy and safety analyses of a 52-week, phase 3, multicenter, open-label study
    Sano, Shigetoshi
    Kubo, Hiroshi
    Morishima, Hitomi
    Goto, Ryosuke
    Zheng, Richuan
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2018, 45 (05): : 529 - 539
  • [49] IL-17 neutralization by subcutaneous CJM112, a fully human anti IL-17A monoclonal antibody for the treatment of relapsing-remitting multiple sclerosis: study design of a phase 2 trial
    Wiendl, H.
    Dahlke, F.
    Bennett, D.
    Rosenkranz, G.
    Wolf, C.
    Bar-Or, A.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 320 - 321
  • [50] Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial
    Kimball, Alexa B.
    Gordon, Kenneth B.
    Langley, Richard G.
    Menter, Alan
    Perdok, Renee J.
    Valdes, Joaquin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2011, 64 (02) : 263 - 274
12345